These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 18790935)

  • 1. Erythropoetic-stimulating agents: where do we stand?
    Dicato M
    Ann Oncol; 2008 Sep; 19 Suppl 7():vii137-40. PubMed ID: 18790935
    [No Abstract]   [Full Text] [Related]  

  • 2. Erythropoiesis-stimulating agents in cancer.
    Arcasoy MO
    J Clin Oncol; 2008 Jun; 26(18):3097-8; author reply 3098-100. PubMed ID: 18565902
    [No Abstract]   [Full Text] [Related]  

  • 3. Updated clinical practice guidelines on erythropoiesis-stimulating agents.
    Silver SM
    Clin Adv Hematol Oncol; 2007 Dec; 5(12):945-6. PubMed ID: 18277954
    [No Abstract]   [Full Text] [Related]  

  • 4. Reconsideration of American Society of Clinical Oncology/American Society of Hematology Erythropoiesis-stimulating Agent Guidelines.
    Murray N; Klasa R
    J Clin Oncol; 2008 Jun; 26(18):3096-7. PubMed ID: 18565901
    [No Abstract]   [Full Text] [Related]  

  • 5. The role of the pharmacist in optimizing the use of erythropoietin stimulating agents.
    Gebara SN; Moubayed H
    J Oncol Pharm Pract; 2010 Mar; 16(1):33-7. PubMed ID: 19401308
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Erythropoiesis-stimulating agents in patients with cancer: update on safety issues.
    Pirker R
    Expert Opin Drug Saf; 2009 Sep; 8(5):515-22. PubMed ID: 19637988
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New ASH/ASCO guidelines on the use of erythropoiesis-stimulating agents: a chorale amid cacophony.
    Steensma DP
    J Support Oncol; 2007; 5(10):471-3. PubMed ID: 18240668
    [No Abstract]   [Full Text] [Related]  

  • 8. Clinical practice guidelines for the use of erythroid-stimulating agents: ASCO, EORTC, NCCN.
    Lichtin AE
    Cancer Treat Res; 2011; 157():239-48. PubMed ID: 21052960
    [No Abstract]   [Full Text] [Related]  

  • 9. [Erythropoiesis-stimulating agents: favorable safety profile when used as indicated].
    Adam M
    Strahlenther Onkol; 2008 Sep; 184(9):490. PubMed ID: 19016030
    [No Abstract]   [Full Text] [Related]  

  • 10. The safety of erythropoiesis-stimulating agents in cancer patients.
    Leyland-Jones B
    Clin Adv Hematol Oncol; 2013; 11(9):596-7. PubMed ID: 24518525
    [No Abstract]   [Full Text] [Related]  

  • 11. Update on erythropoiesis-stimulating agents and clinical trials in oncology.
    Aapro M; Spivak JL
    Oncologist; 2009; 14 Suppl 1():6-15. PubMed ID: 19762512
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Erythropoiesis-stimulating agents in cancer patients: reflections on safety.
    Wauters I; Vansteenkiste J
    Expert Rev Clin Pharmacol; 2011 Jul; 4(4):467-76. PubMed ID: 22114856
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Management of anemia in patients with cancer.
    Steensma DP
    Curr Oncol Rep; 2004 Jul; 6(4):297-304. PubMed ID: 15161584
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Good practice guidelines on the use of erythropoiesis-stimulating agents in 2011.
    Pérez-Oliva Díaz JF
    Nefrologia; 2011; 31(3):361-2. PubMed ID: 21629342
    [No Abstract]   [Full Text] [Related]  

  • 15. Committee releases new guidelines on the use of erythropoiesis-stimulating agents.
    McBride D
    ONS Connect; 2011 Feb; 26(2):19. PubMed ID: 21388023
    [No Abstract]   [Full Text] [Related]  

  • 16. Iron, erythropoietic stimulating agents, and anemia in cancer.
    Adamson JW
    Crit Rev Oncog; 2013; 18(5):471-83. PubMed ID: 23879591
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Erythropoietins should be used according to guidelines.
    Aapro MS; Birgegård G; Bokemeyer C; Cornes P; Foubert J; Gascon P; Glaspy J; Hellström-Lindberg E; Link H; Ludwig H; Osterborg A; Repetto L; Soubeyran P
    Lancet Oncol; 2008 May; 9(5):412-3. PubMed ID: 18452853
    [No Abstract]   [Full Text] [Related]  

  • 18. Erythropoiesis-stimulating agents in the treatment of anaemia in cancer patients: ESMO Clinical Practice Guidelines for use.
    Schrijvers D; De Samblanx H; Roila F;
    Ann Oncol; 2010 May; 21 Suppl 5():v244-7. PubMed ID: 20555090
    [No Abstract]   [Full Text] [Related]  

  • 19. Erythropoiesis stimulating agents, blood transfusion, and the practice of medicine.
    Goodnough LT; Shander AS
    Am J Hematol; 2010 Nov; 85(11):835-7. PubMed ID: 20890909
    [No Abstract]   [Full Text] [Related]  

  • 20. Venous thromboembolic events and erythropoiesis-stimulating agents: an update.
    Dicato M
    Oncologist; 2008; 13 Suppl 3():11-5. PubMed ID: 18458119
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.